指南与共识脊柱关节炎类风湿关节炎

2017年国际工作组更新:轴向和外周脊柱关节炎(尤其银屑病关节炎)达标治疗推荐

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
指南 / 共识 · Ann Rheum Dis · 2017-07-06

国际工作组基于系统文献综述和专家意见更新2012年脊柱关节炎达标治疗推荐,形成5项总体原则和11项推荐,统一覆盖轴向和外周SpA(含PsA)。主要治疗目标为缓解/非活动性疾病或低/极低疾病活动度,推荐ASDAS用于轴向SpA、DAPSA和MDA用于PsA评估,强调医患共同决策。

要点

  • 轴向和外周SpA(含PsA)统一采用缓解/非活动性疾病或低/极低疾病活动度作为主要治疗目标。
  • 推荐ASDAS评估轴向SpA,DAPSA和MDA评估PsA,但并非所有专家支持。
  • 医患共同决策被视为达标治疗过程的关键环节。

核心结论

  • 2017年国际工作组更新推荐,将缓解或低疾病活动度定义为SpA的治疗目标。
  • 形成5项总体原则和11项推荐,统一适用于轴向和外周SpA,包括PsA。

研究设计与样本

  • 国际工作组基于系统文献综述和专家意见制定更新推荐。
  • 工作组由风湿病学家、皮肤科医生、患者和健康专业人员组成。
  • 推荐经过现场讨论、现场投票和后续匿名电子投票确定同意程度。

主要发现

  • 2017年工作组形成一套统一的轴向和外周SpA(含PsA)推荐。
  • 关于PsA应采用单维度复合评分还是多维度评分评估不同领域,讨论最为详尽但未解决。
  • 该未解决问题构成重要研究议程。

关键数值与推荐

  • 推荐ASDAS用于轴向SpA的疾病活动度评估。
  • 推荐DAPSA和MDA用于PsA的疾病活动度评估。
  • 缓解/非活动性疾病或低/极低疾病活动度为主要治疗目标,此共识比2012年获得更多数据支持。

临床怎么用

  • 临床应以缓解或低疾病活动度作为SpA(含PsA)的治疗目标。
  • 轴向SpA使用ASDAS、PsA使用DAPSA或MDA评估患者是否达标。
  • 达标治疗过程中应实施医患共同决策。

局限性

  • 关于PsA应使用单维度复合评分还是多维度评分评估不同领域的问题未解决。
  • ASDAS、DAPSA和MDA作为评估工具的推荐未获得所有专家支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2017. PMID: 28684559. doi:10.1136/annrheumdis-2017-211734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。